Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Ovarian Neoplasms × CB-839 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Rectal Neoplasms 1 Ovarian Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Hereditary Sensory and Autonomic Neuropathies 1 Colonic Neoplasms 1

Interventions

Carboplatin 139 Paclitaxel 136 Bevacizumab 88 Cyclophosphamide 56 olaparib 41 Cisplatin 41 Topotecan 39 Gemcitabine 39 niraparib 37 pembrolizumab 35 liposomal doxorubicin 35 Surveys and Questionnaires 29 Hyperthermic Intraperitoneal Chemotherapy 27 Filgrastim 26 Docetaxel 24 fludarabine 23 Blood Specimen Collection 21 Taxes 20 Drug Therapy 20 Cytoreduction Surgical Procedures 20 Peripheral Blood Stem Cell Transplantation 19 Magnetic Resonance Spectroscopy 19 Doxorubicin 19 Etoposide 18 durvalumab 16 Specimen Handling 16 Albumin-Bound Paclitaxel 15 Letrozole 13 Immunoglobulin G 13 Disulfides 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03944902 2023-11-21

BRCA

University of Alabama at Birmingham

Phase 1 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡